Marcé, S.; Méndez, A.; Xicoy, B.; Estrada, N.; Cabezón, M.; Sturla, A.L.; García, M.R.; Angona, A.; Amat, P.; Escribano Serrat, S.;
et al. e14a2 Transcript Favors Treatment-Free Remission in Chronic Myeloid Leukemia When Associated with Longer Treatment with Tyrosine Kinase Inhibitors and Sustained Deep Molecular Response. J. Clin. Med. 2024, 13, 779.
https://doi.org/10.3390/jcm13030779
AMA Style
Marcé S, Méndez A, Xicoy B, Estrada N, Cabezón M, Sturla AL, García MR, Angona A, Amat P, Escribano Serrat S,
et al. e14a2 Transcript Favors Treatment-Free Remission in Chronic Myeloid Leukemia When Associated with Longer Treatment with Tyrosine Kinase Inhibitors and Sustained Deep Molecular Response. Journal of Clinical Medicine. 2024; 13(3):779.
https://doi.org/10.3390/jcm13030779
Chicago/Turabian Style
Marcé, Sílvia, Aleix Méndez, Blanca Xicoy, Natalia Estrada, Marta Cabezón, Antonella Luciana Sturla, Miriam Ratia García, Anna Angona, Paula Amat, Silvia Escribano Serrat,
and et al. 2024. "e14a2 Transcript Favors Treatment-Free Remission in Chronic Myeloid Leukemia When Associated with Longer Treatment with Tyrosine Kinase Inhibitors and Sustained Deep Molecular Response" Journal of Clinical Medicine 13, no. 3: 779.
https://doi.org/10.3390/jcm13030779
APA Style
Marcé, S., Méndez, A., Xicoy, B., Estrada, N., Cabezón, M., Sturla, A. L., García, M. R., Angona, A., Amat, P., Escribano Serrat, S., Scalzulli, E., Morgades, M., Senín, A., Hernández-Boluda, J. C., Ferrer-Marín, F., Anguita, E., Cortés, M., Plensa, E., Breccia, M.,
... Zamora, L., on behalf of the Grupo Español de Leucemia Mieloide Crónica (GELMC).
(2024). e14a2 Transcript Favors Treatment-Free Remission in Chronic Myeloid Leukemia When Associated with Longer Treatment with Tyrosine Kinase Inhibitors and Sustained Deep Molecular Response. Journal of Clinical Medicine, 13(3), 779.
https://doi.org/10.3390/jcm13030779
